New York City, New York Jun 15, 2022 (Issuewire.com) - At World Hepatitis Summit on 7 June 2022, WHO Director-general advocated in his opening remarks to achieve the elimination of viral hepatitis within evolving health systems. Scientists worldwide have conducted research on hepatitis viruses with several vaccines and drugs proved and will continue to focus on the immune response to infection, pathogenesis, and development of novel therapeutics and vaccines.
Backed by the powerful AntInfect™ Platform designed for antibody and peptide discovery for a viral disease, Creative Biolabs has accumulated extensive experience in this field and has established a comprehensive service portfolio for the discovery of antibody and peptide targeting hepatitis virus.
The first feature of the hepatitis virus-targeted antibody and peptide discovery service is the wide coverage of virus types, which cover all five known virus types, hepatitis A, B, C, D, and E, to help clients rapidly develop effective antibodies & antiviral peptides to prevent, treat and diagnose virus infection.
Besides, the comprehensive technology platform can greatly save clients’ research time by covering the whole pipeline of antibody and peptide development for hepatitis virus. Creative Biolabs tailors different strategies for the biomolecular discovery against diverse targets, using antigen-specific B lymphocytes sorting technology, hybridoma technology, phage display technology, and high-density peptide array. Proprietary protocols and various strategies are employed to identify candidates with higher affinity and desired specificity to meet clients’ development goals. A High-quality and high-throughput functional molecules screening service are also available.
In addition, the scientist team has gained years of experience from managing related projects for regular clients and is familiar with the potential targets for anti-hepatitis antibody or vaccine development, including VP structural protein, surface antigen, core protein, and an envelope protein.
The self-established AntInfect™ Platform allows the project to advance based on a broad range of host species, including but not limited to non-human primate (NHP), mouse, rat, hamster, guinea pig, rabbit, chicken, camel, shark, bovine, dog, goat, sheep, ferret, and alligator. And the platform can offer multiple clones for neutralization activity tests. The results of functional peptide and neutralizing antibodies with high specificity and stability are always ensured at Creative Biolabs.
For more information about anti-virus biomolecular discovery services for hepatitis viruses and other viruses at Creative Biolabs, please visit https://www.creative-biolabs.com/antinfect/.
About Creative Biolabs
As a leading custom service provider in antibody development and engineering, Creative Biolabs has established cutting-edge technologies to support functional biomolecule development for infectious diseases. The service portfolio is comprised of anti-infective antibody and peptide discovery and small molecule drug discovery for a wide range of virus, bacterial, and parasite infections.
Media Contact
Creative Biolabs marketing@creative-biolabs.com https://www.creative-biolabs.com/antinfect/
